ArticleScience translational medicine2017

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Boris Julg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.